Clinical Trial Update: Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission [Phase 2]

View source ↗

Summary

Phase 2 trial of pidilizumab for stage III/IV diffuse large B-cell lymphoma following first remission was terminated; results were posted in March 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Pidilizumab (pidilizumab)

Snippet

Sponsor: Northwestern University | Conditions: Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-03-19